Table 23.
Histology | Age-Group (years) | N d | 1-Year | 2-Year | 5-Year | 10-Year | ||||
---|---|---|---|---|---|---|---|---|---|---|
% | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | |||
Pilocytic astrocytoma | Childrene (0-14) | 2,328 | 98.7 | 98.2-99.1 | 98.3 | 97.7-98.8 | 96.9 | 96.0-97.6 | 95.8 | 94.6-96.7 |
AYAf (15-39) | 1,168 | 97.3 | 96.1-98.1 | 95.8 | 04.4-96.9 | 93.4 | 91.6-94.9 | 90.5 | 88.0-92.5 | |
Adults (40+) | 400 | 94.6 | 91.5-96.6 | 87.3 | 83.1-90.5 | 79.7 | 74.3-84.1 | 76.2 | 69.2-81.8 | |
Diffuse astrocytoma | Childrend (0-14) | 704 | 92.2 | 89.9-94.0 | 87.2 | 84.4-89.5 | 83.0 | 79.9-85.8 | 81.3 | 77.9-84.3 |
AYAe (15-39) | 1,960 | 94.3 | 93.1-95.2 | 87.8 | 86.2-89.2 | 71.4 | 69.1-73.6 | 53.3 | 50.3-56.1 | |
Adults (40+) | 3,480 | 60.1 | 58.3-61.7 | 45.7 | 44.0-46.5 | 31.1 | 29.4-32.8 | 22.0 | 20.1-23.9 | |
Anaplastic astrocytoma | Childrend (0-14) | 235 | 63.1 | 56.4-69.0 | 35.3 | 28.9-41.8 | 23.5 | 17.7-29.8 | 17.5 | 12.0-23.9 |
AYAe (15-39) | 235 | 90.4 | 88.4-92.0 | 76.1 | 73.3-78.6 | 55.4 | 52.0-58.7 | 40.5 | 36.5-44.5 | |
Adults (40+) | 235 | 54.5 | 52.6-56.4 | 34.9 | 33.0-36.8 | 19.7 | 18.0-21.5 | 12.8 | 11.1-14.7 | |
Glioblastoma | Childrend (0-14) | 327 | 52.7 | 47.0-58.0 | 29.5 | 24.4-34.8 | 20.6 | 15.9-25.7 | 16.0 | 11.3-21.4 |
AYAe (15-39) | 1,875 | 74.1 | 72.0-76.0 | 47.7 | 45.3-50.1 | 23.1 | 20.9-25.3 | 14.1 | 12.1-16.3 | |
Adults (40+) | 31,749 | 37.5 | 37.0-38.1 | 15.2 | 14.7-15.6 | 4.3 | 4.0-4.5 | 2.0 | 1.8-2.2 | |
Oligodendroglioma | Childrend (0-14) | 123 | 94.9 | 89.0-97.7 | 94.0 | 87.8-97.1 | 89.1 | 81.6-93.7 | 89.1 | 81.6-93.7 |
AYAe (15-39) | 1,319 | 99.0 | 98.2-99.4 | 97.1 | 95.9-97.9 | 89.4 | 87.3-91.1 | 73.0 | 69.6-76.2 | |
Adults (40+) | 1,820 | 91.2 | 89.7-92.5 | 85.3 | 83.4-87.0 | 74.9 | 72.5-77.2 | 58.5 | 55.2-61.6 | |
Anaplastic oligodendroglioma | Childrend (0-14) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
AYAe (15-39) | 379 | 93.5 | 90.4-95.6 | 85.1 | 80.9-88.5 | 71.6 | 66.2-76.3 | 54.9 | 48.0-61.2 | |
Adults (40+) | 1,006 | 80.1 | 77.4-82.6 | 66.4 | 63.2-69.4 | 51.1 | 47.5-54.6 | 37.9 | 33.8-41.9 | |
Ependymal tumors | Childrend (0-14) | 686 | 94.7 | 92.7-96.2 | 87.2 | 84.3-89.6 | 73.7 | 69.8-77.2 | 64.2 | 59.5-68.5 |
AYAe (15-39) | 820 | 96.9 | 95.4-97.9 | 94.5 | 92.6-95.9 | 90.4 | 87.9-92.5 | 87.2 | 83.7-89.8 | |
Adults (40+) | 1,421 | 92.6 | 91.0-94.0 | 98.7 | 87.7-91.3 | 86.3 | 83.8-88.4 | 82.7 | 79.1-85.7 | |
Oligoastrocytic tumors | Childrend (0-14) | 71 | 97.2 | 88.7-99.3 | 91.0 | 80.8-95.9 | 84.0 | 72.1-9.2 | 81.8 | 69.1-89.7 |
AYAe (15-39) | 937 | 97.2 | 95.9-98.1 | 91.4 | 89.2-93.1 | 75.3 | 72.0-78.4 | 56.2 | 51.6-60.5 | |
Adults (40+) | 1,146 | 81.3 | 78.8-83.6 | 67.1 | 65.1-70.9 | 52.7 | 49.3-55.9 | 41.0 | 37.0-45.0 | |
Glioma malignant, NOS | Childrend (0-14) | 1,624 | 76.4 | 74.2-78.4 | 65.3 | 62.9-67.7 | 62.5 | 60.0-64.9 | 60.9 | 58.2-63.4 |
AYAe (15-39) | 926 | 89.6 | 87.4-91.5 | 82.6 | 79.9-85.0 | 72.6 | 69.2-75.7 | 61.0 | 56.5-65.3 | |
Adults (40+) | 2,256 | 37.4 | 35.2-39.5 | 33.6 | 31.5-35.8 | 30.1 | 27.9-32.3 | 24.9 | 22.4-27.4 | |
Neuronal and mixed neuronal-glial tumors | Childrend (0-14) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
AYAe (15-39) | 139 | 94.9 | 89.5-97.6 | 88.6 | 81.6-93.0 | 78.7 | 68.9-85.1 | 71.3 | 60.2-78.7 | |
Adults (40+) | 384 | 90.0 | 86.2-92.8 | 83.4 | 78.6-87.1 | 75.9 | 70.0-80.8 | 57.3 | 48.3-65.4 | |
Embryonal tumors | Childrend (0-14) | 1,960 | 80.2 | 78.3-81.9 | 70.5 | 68.3-72.5 | 62.3 | 59.9-64.5 | 55.9 | 53.3-58.5 |
AYAe (15-39) | 749 | 87.8 | 85.2-90.0 | 79.6 | 76.4-82.4 | 65.4 | 61.4-69.0 | 58.0 | 53.5-62.2 | |
Adults (40+) | 234 | 73.3 | 66.9-78.7 | 58.3 | 51.3-64.7 | 46.8 | 39.4-53.8 | 35.0 | 27.1-43.0 | |
Meningioma | Childrend (0-14) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
AYAe (15-39) | 93 | 97.9 | 91.3-99.5 | 97.9 | 91.3-99.5 | 89.4 | 79.8-94.6 | 83.1 | 71.4-90.4 | |
Adults (40+) | 1,068 | 73.0 | 69.8-75.8 | 67.8 | 64.4-71.0 | 62.3 | 58.5-65.8 | 54.9 | 50.4-59.1 | |
Lymphoma | Childrend (0-14) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
AYAe (15-39) | 540 | 58.3 | 54.0-62.4 | 53.2 | 48.7-57.4 | 47.5 | 43.0-51.9 | 43.9 | 39.2-48.6 | |
Adults (40+) | 4,239 | 52.0 | 50.4-53.5 | 43.0 | 42.4-44.6 | 31.1 | 29.5-32.8 | 22.7 | 20.9-24.6 | |
TOTAL: All Brain and Other Nervous System g | Children d (0-14) | 9,069 | 85.9 | 85.2-86.6 | 78.6 | 77.7-79.5 | 73.1 | 72.1-74.1 | 69.6 | 68.5-70.7 |
AYA e (15-39) | 13,252 | 89.5 | 89.0-90.0 | 80.9 | 80.2-81.6 | 68.0 | 67.1-68.9 | 56.8 | 55.7-57.9 | |
Adults (40+) | 55,133 | 48.0 | 47.6-48.4 | 30.9 | 30.5-31.3 | 20.3 | 19.1-20.6 | 15.5 | 15.1-15.9 |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, five, and ten years, respectively. Rates were not presented for categories with 50 or less cases and were suppressed for rates where less than 16 cases were surviving within a category.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence -SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (2000-2014) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017, based on the November 2016 submission.
dTotal number of case that occurred within the SEER registries between 2000 and 2014.
eChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.
fAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/adolescent-young-adult.
gTotal includes histologies not listed in this table.
Abbreviation: SEER, Survival, Epidemiology, and End Results; CI, confidence interval; NOS, not otherwise specified.